Compare IOVA & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | ASST |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2008 | 2022 |
| Metric | IOVA | ASST |
|---|---|---|
| Price | $4.08 | $15.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $9.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 12.1M | 4.8M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.84 | ★ 82.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $633,489.00 |
| Revenue This Year | $47.74 | $294.91 |
| Revenue Next Year | $40.31 | $12.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 128.67 |
| 52 Week Low | $1.67 | $0.49 |
| 52 Week High | $5.63 | $19.75 |
| Indicator | IOVA | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 47.11 |
| Support Level | $2.07 | $14.32 |
| Resistance Level | $4.35 | $17.89 |
| Average True Range (ATR) | 0.36 | 1.24 |
| MACD | -0.02 | -0.36 |
| Stochastic Oscillator | 40.45 | 29.47 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.